A growing yellow fever epidemic in Africa and Latin American led to calls for the WHO director-general to convene an emergency response committee, partly because of an anticipated vaccine shortage.
Fonte: Yellow Fever Concerns Grow, WHO Urged to Set Up Emergency Panel
A adoção preferencial do EFV em relação aos IP/RTV na escolha da terapia inicial pelo consenso do MS sempre se deu em bases de fármaco-economia, levando em conta que não havia evidências clínicas de desfecho diferente para as 2 opções. Poe esta meta-análise, é isso mesmo!!!
Agency says risks outweigh benefits
Fonte: FDA: Avoid Cipro, Similar Drugs for Common Infections | Medpage Today
Isso lá. imagina aqui…
Read about the new approved drugs for the treatment of MRSA complicated skin and soft tissue infections.
Fonte: New Therapeutic Options for Skin and Soft Tissue Infections
Embora focado em infecções de pele e partes moles, traz uma bela revisão das mais atuais opções para o tratamento de infecções por MRSA.
Fonte: Angola já reportou mais de 2,1 mil casos suspeitos de febre-amarela | Rádio das Nações Unidas
Preocupante, muito preocupante. De Angola a doença já se fez presente em outros países, podendo sair de controle, no que pese ser uma doença prevenível por vacina.
Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common cause of bacteraemia in endemic countries and may be associated with high mortality; carbapenems are considered the drug of choice. Limited data suggest piperacillin-tazobactam could be equally effective. We aimed to compare 30-day mortality of patients treated empirically with piperacillin-tazobactam versus a carbapenem in a multi-centre retrospective cohort study in Singapore. Only patients with active empiric monotherapy with piperacillin-tazobactam or a carbapenem were included. A propensity score for empiric carbapenem therapy was derived and an adjusted multivariate analysis of mortality was conducted. A total of 394 patients had ESBL-Escherichia.coli and ESBL-Klebsiella pneumoniae bacteraemia of which 23.1% were community acquired cases. One hundred and fifty-one received initial active monotherapy comprising piperacillin-tazobactam (n = 94) or a carbapenem (n = 57). Patients who received carbapenems were less likely to have health-care associated risk factors and have an unknown source of bacteraemia, but were more likely to have a urinary source. Thirty-day mortality was comparable between those who received empiric piperacillin-tazobactam and a carbapenem (29 [30.9%] vs. 17 [29.8%]), P = 0.89). Those who received empiric piperacillin-tazobactam had a lower 30-day acquisition of multi-drug resistant and fungal infections (7 [7.4%] vs. 14 [24.6%]), P<0.01). After adjusting for confounders, use of empiric piperacillin-tazobactam was not associated with increased 30-day mortality (OR 1.00, 95% CI; 0.45-2.17). Empiric piperacillin-tazobactam was not associated with increased 30-day mortality and may result in fewer multi-drug resistant and fungal infections when compared with a carbapenem.
Fonte: Febre amarela causa morte no interior de São Paulo – Notícias – Saúde
Faltam informações mais precisas, como por exemplo qual o critério laboratorial da confirmação do caso ou em que região silvestre teria sido a contaminação, mas a notícia em si é preocupante.
Review Article from The New England Journal of Medicine — Zika Virus
Fonte: Zika Virus — NEJM
Belíssima revisão do conhecimento acumulado até o momento, publicado na NEJM.
Correspondence from The New England Journal of Medicine — Computed Tomographic Findings in Microcephaly Associated with Zika Virus
blog infectologia em geral 